MicroPort® CRM Announces European Launch of World's Smallest 1.5T & 3T MRI Conditional Pacemaker Portfolio*

Clamart, France – January 03rd, 2019 - MicroPort® CRM (a business unit of MicroPort Scientific Corporation), is pleased to announce the European launch of its next generation MR-conditional transvenous pacing systems. This launch sees the introduction of three new pacemaker families: Eno™, Teo™ and Oto™.
All models in the three new pacemaker families are full-body MR-conditional, allowing patients implanted with compatible leads to undergo MRI (Magnetic Resonance Imaging) scans in either 1.5 Tesla or 3 Tesla machines without any exclusion zones, permitting physicians to perform MRI scans on all areas of the body.
In addition, the new products Eno™, Teo™ and Oto™ feature AutoMRI™ technology, enabling implanted pacemakers to automatically switch in and out of MRI mode upon detection of the MR field. AutoMRI™ ensures appropriate pacemaker operation during the scan and allows patients to benefit from optimal pacing settings right up to and just after the scan.
The new pacemaker portfolio also features :
- Phi Intelligence™: a permanent adaptive pacing strategy that responds to all levels of patient activity, day and night, evolving and learning with the patient’s conditions in order to mimic the natural way the heart works, minimizing artificial intervention.
- AF Risk Management™: a unique combination of features that helps physicians to accurately detect Atrial Fibrillation (AF), minimize ventricular pacing and screen for sleep apnea so as to protect patients from developing AF.
- Preset Fit™: a set of capabilities including precision programming calibrated through clinical experience and designed to facilitate the implant procedure and device follow up.
"Our customers have been very pleased with the technology and therapeutic functions we have introduced in our pacemakers year after year," commented Benoît Clinchamps, President of MicroPort® CRM. "Augmented with the capability to undergo 3T MRI scans, the introduction of these three new pacemaker families builds on our strengths, offering state-of-the-art pacing therapies."
*Transvenous cardiac pacing systems.

About MicroPort® CRM
Pioneering physiological therapies in cardiac rhythm management. Driven by our expert R&D teams and state-of-the-art manufacturing facilities across the globe, MicroPort® CRM conceives, designs and develops solutions for the management of cardiac rhythm disorders and heart failure. Headquartered in Paris, our precise technologies are manufactured in France, Italy, the Dominican Republic; and for the Chinese market, in China. MicroPort® CRM is part of MicroPort Scientific Corporation.
For more information visit www.crm.microport.com